• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nicotine Addiction - Pipeline Review, H2 2012 Product Image

Nicotine Addiction - Pipeline Review, H2 2012

  • ID: 2366343
  • December 2012
  • 74 pages
  • Global Markets Direct

Nicotine Addiction – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Nicotine Addiction - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nicotine Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nicotine Addiction. Nicotine Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nicotine Addiction.
- A review of the Nicotine Addiction products under development by companies and universities/research READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Nicotine Addiction Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Nicotine Addiction 9
Nicotine Addiction Therapeutics under Development by Companies 11
Nicotine Addiction Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Nicotine Addiction Therapeutics – Products under Development by Companies 18
Nicotine Addiction Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Nicotine Addiction Therapeutics Development 20
Nabi Biopharmaceuticals 20
Novartis AG 21
EnVivo Pharmaceuticals 22
Omeros Corporation 23
Selecta Biosciences, Inc. 24
Heptares Therapeutics Ltd. 25
Celtic Pharmaceutical Holdings L.P. 26
Beech Tree Labs, Inc. 27
Nicotine Addiction – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
GW-468816 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NicVAX - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NIC-002 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EVP-6124 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cycloserine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
varenicline tartrate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
topiramate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TA-NIC - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
propranolol hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Modafinil + Nicotine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Relapse Prevention Treatment + Varenicline - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BTL-ng - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OMS-527 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
OMS-403 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
varenicline tartrate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cognitive Behavioral Therapy + Nicotine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SEL-068 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug targeting Orexin 1 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nicotine Vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Nicotine Addiction Therapeutics – Drug Profile Updates 63
Nicotine Addiction Therapeutics - Dormant Products 67
Nicotine Addiction – Product Development Milestones 68
Featured News & Press Releases 68
Oct 10, 2012: Perrigo Receives FDA Approval To Market Mini Nicotine Lozenges 68
Jul 21, 2011: Perrigo Receives FDA Approval To Market Coated Cinnamon Nicotine Gum 68
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 68
Nov 05, 2010: Novartis Announces Initiation Of New Clinical Study With Nicotine Vaccine NIC002 69
Nov 08, 2007: Acrux Develops Nicotine Spray To Help Smokers Quit 70
Oct 29, 2007: Celtic Pharma Completes Rapid Enrollment In Phase IIB Study For TA-NIC (TANIC) The Nicotine Vaccine For Smoking Cessation 70
Apr 30, 2007: Celtic Pharma Receives IND Approval To Initiate A Large Randomized Study In The US For TA-NIC, Its Immunotherapy Vaccine For The Treatment Of Smoking Cessation 71
May 08, 2006: Celtic Pharma Announces Launch Of Phase II Clinical Trial For TANIC, A Vaccine Treatment For Nicotine Addiction 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products Under Development for Nicotine Addiction, H2 2012 9
Products under Development for Nicotine Addiction – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Nabi Biopharmaceuticals, H2 2012 20
Novartis AG, H2 2012 21
EnVivo Pharmaceuticals, H2 2012 22
Omeros Corporation, H2 2012 23
Selecta Biosciences, Inc., H2 2012 24
Heptares Therapeutics Ltd., H2 2012 25
Celtic Pharmaceutical Holdings L.P., H2 2012 26
Beech Tree Labs, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Nicotine Addiction Therapeutics – Drug Profile Updates 63
Nicotine Addiction Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Nicotine Addiction, H2 2012 9
Products under Development for Nicotine Addiction – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos